{"id":28304,"date":"2016-10-10T12:11:10","date_gmt":"2016-10-10T10:11:10","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=28304"},"modified":"2018-05-04T19:28:12","modified_gmt":"2018-05-04T17:28:12","slug":"mylan-patteggia-sullepipen-e-vola-in-premarket-al-nasdaq-10","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/mylan-patteggia-sullepipen-e-vola-in-premarket-al-nasdaq-10\/","title":{"rendered":"Mylan trades on EpiPen and flies in premarket on Nasdaq (+10%)"},"content":{"rendered":"

Mylan earns more than 10% in premarket on the Nasdaq (Friday's session closed with a decline of 2.44%), after the US pharmaceutical group (which, however, has its fiscal headquarters in the Netherlands) surprisingly announced on Friday that it had reached an agreement with the US Justice Department to settle the disputes related to the controversial EpiPen Auto-Injector (an instrument for administering epinephrine mainly in cases of anaphylactic shock).<\/p>\n

Mylan will pay $465 million in fines but will not have to admit to having committed any wrongdoing. The agreement arrived in record time given that just two weeks ago the Centers for Medicare and Medicaid Services (Cms, the US federal body that administers health insurance programs and in particular the reimbursement of drugs) had accused Mylan of having improperly classified the EpiPen as a generic product so as to be able to apply more limited discounts to Medicare and Medicaid (the 13% against the 23% due given that the drug, innovative, is in a substantial monopoly regime: the group has around 80% on the market).<\/p>\n

(RR \u2013 FTA Online News)<\/span><\/p>\n

10\/10\/2016 \u2013 THE PRESS Economy<\/span><\/a><\/p>\n

Related news:\u00a0Mylan to settles EpiPen overpricing Case for $ 465 million<\/span><\/a><\/p>\n

What is behind Mylan's strategy to contain the crisis created by the exorbitant price of the EpiPen?<\/a><\/span><\/p>\n

Super-increase in the price of a lifesaver (+ 400%), Mylan under attack in the USA<\/a><\/span><\/p>\n

Hepatitis C, European Patent Office withdraws protection on sofosbuvir<\/span><\/a><\/p>","protected":false},"excerpt":{"rendered":"

Mylan guadagna oltre il 10% in premarket al Nasdaq (la seduta di venerd\u00ec si era chiusa con un declino del 2,44%), dopo che a sorpresa venerd\u00ec a mercati chiusi il gruppo farmaceutico Usa (che ha per\u00f2 sede fiscale in Olanda) aveva comunicato di avere raggiunto un accordo con lo U.S. Justice Department per chiudere i …<\/p>","protected":false},"author":4,"featured_media":27727,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-28304","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/28304","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=28304"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/28304\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/27727"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=28304"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=28304"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=28304"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}